Retard implantation tablets on a matrix base with Eudragit as a structural substance.
A model for prolonged availability of low concentrated drugs was successfully tested by using 7-hydroxyethyltheophylline and Eudragit RS 100 as matrix to form implant-tablets. Those tablets have the same size, same weight, same hardness, but a different concentration of the model substance and are coated with liquid Eudragit RS 100. Statistical evaluation of the different liberation rates led to a drawing of a diagram whereby a desired drug liberation up to 6 d can easily be obtained by choosing a certain drug concentration of the tablet.
D000180:Acrylic Resins / Q000008:administration & dosage; D004339:Drug Compounding; D004343:Drug Implants; D005079:Excipients; D011109:Polymethacrylic Acids; D013607:Tablets; D013806:Theophylline / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors
D000180:Acrylic Resins; D004343:Drug Implants; D005079:Excipients; D011109:Polymethacrylic Acids; D013607:Tablets; C038300:methylmethacrylate-methacrylic acid copolymer; D013806:Theophylline; C008749:etofylline